197
Participants
Start Date
May 31, 2017
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2024
Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]
Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Nivolumab 100 MG/10 ML [Opdivo]
Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Epirubicin
Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Ifosfamide
Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Doxorubicin
Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Dacarbazine
Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Cisplatin
Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Methotrexate
Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Candiolo Cancer Institute - FPO, IRCCS, Candiolo
Istituto Nazionale dei Tumori, Milan
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna
Istituto Ortopedico Rizzoli, Bologna
Hospital Universitario Virgen del Rocío, Seville
Hospital Universitari i Politècnic La Fe, Valencia
Hospital Universitario Miguel Servet, Zaragoza
Hospital Universitari Vall d'Hebrón, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
University College London Hospitals NHS Foundation Trust, London
Grupo Espanol de Investigacion en Sarcomas
OTHER